Celyad Oncology S.A.
CYAD
Classifica tra le azioni
#31444
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Prezzo delle azioni
$0.25502336
Capitalizzazione di mercato
$12.05M
Variazione (1 giorno)
-5.29%
Variazione (1 anno)
-12.17%
Paese
BE
Scambia Celyad Oncology S.A. (CYAD)
Categoria
Healthcare
Capitalizzazione di mercato di Celyad Oncology S.A.(CYAD)
Capitalizzazione di mercato: $12.05M
A partire dal October 2026, Celyad Oncology S.A. ha una capitalizzazione di mercato pari a $12.05M. Questo rende Celyad Oncology S.A. la 31444th azienda più preziosa al mondo per capitalizzazione di mercato secondo i nostri dati. La capitalizzazione di mercato è il valore totale delle azioni in circolazione di una società quotata e viene comunemente utilizzata per misurarne il valore.
Storia della capitalizzazione di mercato di Celyad Oncology S.A. dal 2014 al 2026
CYAD in paragone con la classifica dei più popolari stocks
| Il prezzo per CYAD | Attivo B | Capitalizzazione del mercato a B | Risultati | |
|---|---|---|---|---|
$124,722
$21.57M
|
$5.167T | +23,951,571.81% | ||
|
$121,046
$21.57M
|
$5.015T | +23,245,770.87% | ||
|
$99,168.33
$21.57M
|
$4.108T | +19,044,285.53% | ||
|
$94,183.88
$21.57M
|
$3.902T | +18,087,067.56% | ||
|
$64,917.90
$21.57M
|
$2.689T | +12,466,799.51% |
